GlassScriptPhysician profile
Vanessa Sims
NPI 1124431382
$2,513.40
in general payments reported to CMS, 2019-2025
23 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $484 · 2023: $371 · 2024: $502 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $921.39 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $439.81 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $314.12 | 2021-2025 | Caplyta |
| Amgen INC. | $109.66 | 2021 | |
| Indivior INC. | $100.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $81.05 | 2021 | |
| Averitas Pharma INC. | $60.88 | 2023 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $59.17 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.18 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $52.88 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $50.43 | 2022 | |
| Currax Pharmaceuticals LLC | $41.59 | 2021 | |
| Orexo US, INC. | $40.78 | 2022-2023 | Zubsolv |
| Glaxosmithkline, LLC. | $30.17 | 2023 | Trelegy Ellipta, Shingrix |
| Bausch Health US, LLC | $22.34 | 2025 | Wellbutrin, Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $21.28 | 2025 | Xyosted |
| Biogen, INC. | $21.26 | 2024 | |
| Exact Sciences Corporation | $19.87 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $16.38 | 2025 | Auvelity |
| Novo Nordisk INC | $15.20 | 2021 | |
| Lilly USA, LLC | $14.21 | 2024 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $13.42 | 2023 | Quviviq |
| Amarin Pharma, INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.